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Abstract
This article provides an ethnographic account of how Big Data biology is produced, interpreted, debated, and translated
in a Big Data-driven cancer clinical trial, entitled “Personalized OncoGenomics,” in Vancouver, Canada. We delve into
epistemological differences between clinical judgment, pathological assessment, and bioinformatic analysis of cancer. To
unpack these epistemological differences, we analyze a set of gazes required to produce Big Data biology in cancer care:
clinical gaze, molecular gaze, and informational gaze. We are concerned with the interactions of these bodily gazes and
their interdependence on each other to produce Big Data biology and translate it into clinical knowledge. To that end,
our central research questions ask: How do medical practitioners and data scientists interact, contest, and collaborate
to produce and translate Big Data into clinical knowledge? What counts as actionable and reliable data in cancer
decision-making? How does the explicability or translatability of genomic Big Data come to redefine or contradict
medical practice? The article contributes to current debates on whether Big Data engenders new questions and
approaches to biology, or Big Data biology is merely an extension of early modern natural history and biology. This
ethnographic account will highlight how genomic Big Data, which underpins the mechanism of personalized medicine,
allows oncologists to understand and diagnose cancer in a different light, but it does not revolutionize or disrupt medical
oncology on an institutional level. Rather, personalized medicine is interdependent on different styles of (medical)
thought, gaze, and practice to be produced and made intelligible.
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Introduction
Trish Keating is the “poster child” for the Personalized
OncoGenomics (POG) experimental clinical genomics
cancer trial, located in Vancouver, British Columbia.
A retired film costume designer, she was diagnosed
with stage-four colorectal cancer in 2010 which had
metastasized to other organs in her body. Traditional
cancer treatments including chemotherapy, radiation,
and surgeries failed to treat her cancer. As her cancer
grew more aggressive, Trish became palliative and pre-
pared for her last few months on earth. Trish enrolled
in POG as a last resort. POG used whole genome
sequencing, machine learning, and other computation-
al techniques to process and analyze biomedical Big
Data to identify patterns and abnormalities in the
tumor genome. Trish’s DNA and RNA sequencing
data showed a curious biomarker, which is a protein
responsible for the growth of her tumors. This specific
protein can be easily inhibited by a high blood pressure
medication. Within five weeks of starting on a low-cost
high blood pressure drug her tumors went into remis-
sion. News articles and documentaries called Trish’s
case both a miracle and a scientific breakthrough of
genomic sciences in oncology care.
Doctors agreed with the media. They called it mirac-
ulous that a common blood-pressure drug can inhibit
the growth of aggressive cancer tumors where
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standardized cancer treatments, including radiation
and chemotherapy, failed (Fayerman, 2015). What
does this “miracle” signify? Trish Keating’s case
shows a rise in computational approach to cancer,
which uses computational analysis to understand
cancer in terms of numbers, measurement levels, and
statistical correlations. Trish Keating’s case exemplifies
the ways in which Big Data can influence clinical
decision-making. However, for Big Data to be applied
into clinical decisions it is helpful to explore the pro-
cesses of how Big Data is collected, processed, and
transformed from the human flesh and translated
into clinical knowledge.
Our research contributes to critical-interpretive per-
spectives of the use of Big Data in the healthcare
domain (Stevens et al., 2018). It also contributes to
current debates on whether Big Data engenders new
questions and approaches to biology (Ratti, 2016;
Stevens, 2013, 2016), or Big Data biology is merely
an extension of early modern natural history and biol-
ogy (Leonelli, 2014; Strasser, 2012; Strasser and
Edwards, 2017). While these discussions center
around the nature and value of Big Data biology and
the production of Big Data in genomic laboratories,
little has been written about how Big Data is produced
and translated into clinical decision-making.
In this article, we examine the production and trans-
lation of Big Data into clinical genomics, which is a
complex biomedical process that comprises two or
more epistemological systems of knowledge about
cancer. The article explores epistemological differences
between bioinformatic analysis and pathology assess-
ment of cancer. The former focuses on large-scale data
points of gene expression produced from statistical
analyses, and the latter is concerned with protein
expression of tumors obtained from microscopic stud-
ies. We conducted an ethnography with a Big Data-
driven cancer clinical trial, entitled “Personalized
OncoGenomics”, located in Vancouver, Canada.
POG is a cutting-edge collaborative project between
radiology, pathology, molecular biology, bioinformat-
ics, and oncology. It is an ideal site to observe and
understand how genomic Big Data is produced, inter-
preted, contested, and actioned in a clinical setting.
These questions drive our research: How do medical
practitioners and data scientists interact, contest, and
collaborate to produce and translate Big Data into clin-
ical knowledge? What counts as actionable and reliable
data in cancer decision-making? And how does the
explicability or translatability of genomic Big Data
come to redefine or contradict medical practice?
POG helps us understand how cancer and the body
multiple (Mol, 2002) through the different gazes and
how these different practices come together to render
meaningful clinical knowledge of life itself. We study
three types of actors at POG, radiologists, pathologists,
bioinformaticians, and oncologists, to observe and
understand how each makes sense and enacts knowl-
edge about cancer and the body. They each operate
from their own perspectives and gazes: a clinical gaze,
molecular gaze, and informational gaze (Foucault,
1963; Kay, 2000; Rose, 2007). We examine their indi-
vidual characteristics, interactions, and interdepend-
ences as they produce Big Data biology and translate
it into clinical knowledge. We argue Big Data biology
and clinical work are interdependent on one another in
the realm of oncogenomics and the entrance of geno-
mic Big Data does not automatically translate into clin-
ically useful knowledge. This ethnographic study
highlights how genomic Big Data allows oncologists
to understand and diagnose cancer using data-driven
methods. The genomic data is new, but it does not
necessarily revolutionize or disrupt medical oncology
on an institutional level. We observe a highly collegial
and interactive collaborative network of professionals
in which clinicians still act as the gatekeeper to medical
action. Their medical judgment, expertise, and ethics
hold a higher authority than data-driven approaches
in clinical decision-making. Most importantly, our eth-
nographic data sheds light on what stakeholders felt
was really at stake in the adoption of Big Data into
oncology setting, which is the life of the patient.
The “non-revolutionary” convergence
of Big Data and biology in cancer
genomics trials
Scholars in social studies of biomedical innovation
have extensively investigated “bioclinical collectives”
of multidisciplinary experts and disciplines that make
up new ways of practicing medical care (Bourret, 2005;
Cambrosio et al., 2014; Rabeharisoa and Bourret,
2009; Timmermans et al., 2017). “Bioclinical collec-
tives’’ of cancer clinical trials attend to the ways in
which different epistemologies collaborate, contest,
negotiate, and co-construct knowledge of cancer.
With the proliferation of molecular biology and high-
throughput genomic technologies, oncology care has
embraced a new form of “experimental care” in
which the boundaries between research and care as
well as biology and computing sciences have been
blurred (Cambrosio et al., 2018; Keating and
Cambrosio, 2011; Nelson et al., 2013). Such epistemo-
logical blurring has led to opportunities in understand-
ing cancer in a new light. Genomic medicine gives rise
to a new “sociotechnical regime” in oncology (Nelson
et al., 2013: 407). While “actionable” genomic data
influences clinical decisions, it also shifts “the types of
evidence on which clinicians can act” (Nelson et al.,
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2013: 425). Big Data biology also engenders challenges
in translating computational data into clinically action-
able knowledge. The translatability of Big Data into
clinical settings is an important topic, which is current-
ly understudied in critical data studies. Many studies
have focused on how bioinformaticians analyze
and produce biological knowledge from Big Data
(Stevens, 2011, 2013, 2016). Less attention has been
paid to other medical practitioners, such as radiologists
or pathologists who also play vital roles in the produc-
tion of biological samples that are later sequenced into
Big Data. This ethnography attends to a set of medical
practices employed by these different cancer specialists
to extract, process, and assess cancer tumor samples
that are transformed into Big Data and then translated
into clinical knowledge. The ethnography sheds light
on the multidirectional and multi-modal flows of het-
erogeneous materials, information, and knowledge
(Crabu, 2016) in the re-inscription of human tumor
flesh into genomic Big Data. It also contributes to
the current debates on the impacts of Big Data in clin-
ical practices.
Data-driven or data-centric approaches to medicine
have been a prolific topic of discussion for many schol-
ars in the history of science, communication, and phi-
losophy of (big) data. Most of the literature about Big
Data in health tend to focus on the ethics, ownership,
and governance of data and databases (Ostherr et al.,
2017; Prainsack, 2019; Sharon and Lucivero, 2019).
Others focus on the economic impacts of Big Data
and information in healthcare (Stevens, 2011;
Vezyridis and Timmons, 2017). More importantly, an
ongoing debate on Big Data biology centers around the
differences between Big Data biology and traditional
biological practices. Historian of science Bruno
Strasser (2012) posits that Big Data science is deeply
rooted in early modern natural history, and hence,
data-driven science is not a novel invention.
According to Strasser (2012), a fundamental difference
between contemporary data-driven science and early
modern natural history concerns the nature of the
data. He argues that while the former relies on peta-
bytes of digital data stored in computerized databases,
the latter mainly comprises “analog images” and
“scientific objects” stored in “closed boxes” and library
archives (p. 86). A second difference, Strasser contin-
ues, stems from the proliferation of data analysts in
contemporary data sciences, who analyze data sent to
them by other stakeholders and do not necessarily col-
lect or produce any data themselves. Whereas in the
early modern periods, naturalists such as Darwin or
Cuvier tended to be the ones who analyzed the data
that they themselves collected or produced. Therefore,
Strasser concludes that the characteristics of contem-
porary data-driven science are not different from
hypothesis-driven methods of early modern natural
history. Historian and philosopher of science, Sabina
Leonelli (2014), also challenges the “revolutionary”
discourse of Big Data. She argues the mechanisms
of Big Data are well-aligned with the core
epistemologies of early modern biology in conducting
“explanatory experimentation, sampling and the search
for causal mechanisms” (p. 9). As such, Big Data does
“make a difference” in biology, just in “non-revolu-
tionary” ways.
Other scholars, however, argue Big Data can trans-
form biology by engendering new questions and
approaches (Chow-White and Garcıa-Sancho, 2012;
Stevens, 2013, 2015, 2016). Historian of science
Hallam Stevens (2016) examines the implications of
text-search algorithms, a text-mining tool in Big Data
research, in reconceptualizing genomics not as biolog-
ical properties but as text-based information. To
Stevens, biostatisticians or bioinformaticians are less
concerned about the biological meanings of DNA
than with finding “commonly occurring or overrepre-
sented patterns” (p. 364) in a large dataset. Therefore,
Big Data can enable new approaches to understanding
human biology as large-scale text-based entities and
change the ways in which the human genome is ontolo-
gized. However, conceptualizing DNA as text-based
entities limits “the kinds of questions and answers that
genome biologists pose and attempt to answer” (p. 353).
While much research has focused on the production,
sharing and control of Big Data, or “data journeys” in
laboratories and research institutions (Leonelli, 2016;
Stevens, 2011), relatively little research has examined
the ways in which Big Data is produced, negotiated,
and translated into clinical knowledge. This article is
set out to fill that gap by documenting the production
or re-inscription process of cancer tumor into Big
Data, followed by three vignettes that depict the trans-
latability, or the lack thereof, of Big Data into action-
able clinical knowledge. We examine various medical
practices required to produce and analyze Big Data
within cancer research by looking at how human
flesh and tumors become data and how data analysis
is negotiated and translated into clinical care. This crit-
ical examination shows how actors produce cancer Big
Data from traditional biological practices and worked
into medical diagnosis, rather than transforming med-
ical practices altogether. The ethnography of this arti-
cle highlights a complex amalgam of clinical,
molecular, and bioinformatic gazes of seeing, feeling,
and understanding the cancer in terms of fleshy forms,
molecular cells, and bits and bytes information system
(Kay, 2000). Our analysis seeks to further advance the
discussion on life as information by examining how
seeing the cancer as an information system by the bio-
informatician can complement or contradict the
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clinician’s way of seeing and gazing at the cancer
through medical intuition and ethics.
The bodily gazes
Scholars argue bodies have always been subjects under
one or more forms of gaze, whether it is the clinical
gaze, the male gaze, and/or the white gaze. The
“clinical gaze” helps us understand the ways in which
traditional diagnosis is established on the basis of ana-
tomical pathology, which is an observable association
between pathological structures and bodily syndromes
(Foucault, 1973). As we enter a post-genomics era,
individuals are increasingly subject to a gaze that ren-
ders the bodies and their biology as numerical, measur-
able, and informational. We call this an “informational
gaze”. The informational gaze is an extension of the
“molecular gaze,” a concept developed by sociologist
Nikolas Rose (2007). Rose conceptualizes the molecu-
lar gaze as a molecular style of thought about life itself
in terms of variations in nucleotide sequences and
molecular mechanisms of gene and protein expressions,
which renders life molecular (Myers, 2015). When the
ontology of life takes a molecular turn, biological com-
ponents of the body including cells, tissues, DNA,
RNA, or proteins can be fragmented, decomposed, sta-
bilized, frozen, extracted, manipulated, commodified,
and capitalized. Genomic technologies are embedded
with these molecular practices of extracting, construct-
ing, and sequencing DNA and RNA for comprehensive
transcriptome and gene expression analysis. These
comprehensive analyses of our molecules are analyzed
and understood using large-scale informational data,
computational codes, and probabilistic values. In
other words, the molecular forms of life are made
intelligible by processes of calculation, quantification,
measurement, and informatization. Thus, in the post-
genomic age, the body may still be understood in
terms of their molecules, but their molecules have
taken on a form of information, data, and numerical
values. To this end, the body along with the normal
and the pathological are seen as an informational
system. This is the core of the informational gaze.
The informational gaze reflects a profession vision
(Goodwin, 1994) of doctors and scientists who use
Big Data analyses and statistical visualization to
draw pathways and causation between tumors, muta-
tions, and markers. Traditional biology views the
body in terms of cells and molecules. Under the
regime of Big Data biology, the body is understood
in forms of codes, numbers, and information. Whole
genome and transcriptome sequencing are common
methods for producing this information. In an
exchange with a leading genome scientist in
Vancouver, Canada, the scientist shared with us the
reason POG chose to do whole genome and transcrip-
tome rather than just whole exome sequencing, which
is cheaper and produces less data to analyze. The
bigger the data captured, the higher chance to pro-
duce statistically significant probability value and
minimize any margins of error:
I want the whole thing. Until you measure the genome,
you don’t know what you have missed and so I don’t
want to miss the answer and I don’t think we need to
miss the answer. We deal with complex information
systems. That’s what the genome center does. We are
experts in whole genome and transcriptomes. We can
do transcriptomes. That’s not the point. The more
important point is, when you look at the observations
we make in POG that are most likely to impact clinical
course of action, the transcriptome is the dominant
feature. Then aspects of the genome that support the
transcription become very important. We need it all.
We can’t be fooling around with one percent of the
genome. (Genome Scientist)
This response signifies a kind of “data fever,” showing
how we become feverish in capturing and “need[ing] it
all,” as we generate and rely on Big Data for making
senses of the body and the world. It also reflects the
perception of the body in the informational gaze, not as
biological properties but as “complex information sys-
tems”. The body as information systems becomes a
commodity fetish to be rendered into large-scale data-
sets for knowledge pursuit and/or pharmaceutical dis-
coveries. The informational gaze interacts with the
clinical and the molecular ones in clinical settings,
more particularly in oncology care. Although these
gazes have different epistemological approaches to
understanding cancer, in the case of POG they are
not pure or distinct from each other. Rather, these dif-
ferent gazes interact with, contest, and influence one
another to produce and translate Big Data into clini-
cally actionable knowledge. The outcomes of these
interactions are knowledge exchange and educational
opportunities for various stakeholders to learn from
each other through their collaboration, and more
importantly, better-informed clinical decisions for pro-
longing life of the cancer patient.
“Personalized Oncogenomics” cancer
clinical trial
POG is a flagship research program at the Genome
Science Center (GSC) in collaboration with British
Columbia Cancer Agency (BCCA) and Vancouver
Cancer Center (VCC). POG’s weekly board meeting
takes place at the BCCA’s BC Cancer Research
4 Big Data & Society
Centre (BCCRC) building, while the sequencing work
happens at GSC. The GSC and BCCRC are two sep-
arate buildings located a few blocks away from each
other. BCCRC is located across the street from VCC
where most cancer patients are treated, and cancer spe-
cialists are located. The GSC is located in a typical
eight-storey office building, framed with red brick
and large glass windows, between Cambie and West
7th Streets in a non-descript block of low-rise office
buildings mixed with residential services and busi-
nesses. It is an area of Vancouver that is home to
Vancouver General Hospital and one of the largest
clusters of medical services in North America, includ-
ing the University of British Columbia Medical
School’s teaching campus. GSC was founded by
Michael Smith—a Canadian Nobel Laureate in
Chemistry awarded in 1999. The role of GSC is two-
fold: research department and technology platform of
both sequencing and bioinformatics. The GSC pio-
neered next-generation sequencing technology in sup-
port of life sciences research of both cancer and
infectious diseases. Today, the GSC is one of the
most advanced genome research centers in Canada
and a world class facility for publications and high
throughput and DNA sequencing which has produced
“more than 2.2 peta-bases (2.2 1015) of DNA
sequence, equivalent to the number of base-pairs in
660,000 human genomes” (BCGSC, 2019). In other
words, GSC has produced a massive amount of
human genome data.
Each patient at POG undergoes a tumor biopsy and
has comprehensive DNA and RNA sequencing. Tumor
sequencing can produce about 600 GB of raw data that
requires a lot of computational power of coding to
analyze. That job goes to bioinformaticians who per-
form analyses using computer algorithms including
machine learning and statistical analyses to identify
variants that may be cancer “drivers”. Then, oncolo-
gists use the results to identify any known drugs that
can target the cancer drivers. Before the oncologist
applies these data in their clinical decision, POG
holds a weekly tumor board meeting every Thursday.
The weekly meeting brings together a group of multi-
disciplinary scientific and medical experts to discuss
different patient cases.
We summarize the POG pipeline in Flowchart 1
(Figure 1) to provide an overview of the process of
transforming cancer tumor in its fleshy form into com-
putational Big Data. The flowchart visualizes a pipeline
production that starts with a biopsy process done by an
interventional radiologist at the VCC. POG withdraws
blood samples from the patient to use as the germline
genome to compare and contrast with the patient’s
tumor samples, the somatic genome. Their tumor sam-
ples are sent to a pathology department also at the
VCC for quality assessment. Both the blood and the
tumor samples are then transferred to the 5th floor of
the GSC for DNA and RNA Library Core
Construction. Next, the DNA & RNA libraries are
then sequenced in a HiSeq machine produced by
Figure 1. POG flowchart: Multiple gazes of the cancer.
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Illumina on the 6th floor of the GSC building. The
whole genome sequencing takes about three to four
days to produce the raw genomic data. This dataset
is then sent to a bioinformatics team for downstream
quality control and analysis. The genomic analysis
focuses on causal relationships between the genes and
DNA and the causes of pathogenic variants that drive
the growth of cancer cells. The end result is a genomic
pathway that resembles a datafied map of what drives
the cancer tumor. This datafied map illustrates an algo-
rithmic pathway of cancer, encompassing expressional
levels and other numerical measurements, biomarkers,
mutations, alleles, and proteins. In other words, we
have reached a complete informational inscription of
our DNA and RNA. In what follows, we are going to
delve into different practices, visions, and tensions
among this multidisciplinary group of medical experts
at POG precisely to highlight the interactions between
the clinical gaze, the molecular gaze, and the informa-
tional gaze in the production and translation of geno-
mic Big Data. Through these multiple gazes, we can
also see multiple versions of cancer in the forms of
flesh, of cells and molecules, and of Big Data. In
what follows, we describe the biomedical pipeline of
POG that inscribes bodily tissues into Big Data. We
will then discuss three vignettes highlighting the inter-
actions between various practices in their efforts to
translate Big Data into actionable and meaningful
knowledge.
The cancer multiple
Radiology (clinical gaze): Rawness of the flesh
In summer 2017, we started shadowing scientists at
POG in their laboratory to observe scientific processes
of extracting DNA from human tumors and normal
samples and constructing DNA library from these sam-
ples. Along with these observations, we also obtained
31 interviews with different medical actors involved
with POG pipeline of extracting, assessing, sequencing,
and analyzing both normal and pathological samples
of the patient. The first step of the pipeline is a tumor
biopsy, a physical extraction of a tumor sample from
the cancer cell located inside the body. The interven-
tional radiology department, specialized in tumor
biopsy, is located on the 4th floor of VCC. We had
an interview appointment with radiologist Doctor
Farred.1
Walking into Dr Farred’s office, he was diligently
going through ultrasound and PET scan images of dif-
ferent cancer patients. He seemed highly skilled and
disciplined. His eyes were stuck onto the screen while
greeting one of the researchers on our team. He was
comparing one image to another, identifying tumor
locations, and making some kind of tacit decisions in
his head regarding the quality of the tumors and how
to extract them. At this moment, Dr Farred exerted a
clinical gaze into the cancer through image-guided
technology of ultrasound, PET scans, and MRI. Dr
Farred obtained this clinical gaze through years of spe-
cialized training of studying medical images to diag-
nose cancer. To an interventional radiologist like Dr
Farred, cancer remains as a physical property projected
through images.
Dr Farred also performed biopsy on patients, in
other words, an extraction of cancer tumor samples.
Tumor biopsy is a standard procedure in oncology.
However, tumor biopsy for genomic sequencing
requires higher levels of cellularity than standard biop-
sies in order for the sample to yield higher content of
DNA and RNA. As such, interventional radiologists,
who are in charge of the biopsy process, typically need
to use ultrasound to identify the most appropriate site
of the lesion to extract. The POG biopsy also requires
cells that are still active, and not necrotic, because these
cells are later broken down and blended to release var-
ious enzymes. As such, a sample with a lot of necrotic
tissues can damage the cellularity of the sample and fail
to provide sufficient data for downstream analysis.
POG biopsy samples strictly require cancer cells, and
not normal cells, for sequencing and analysis. In the
bodily milieu, normal and pathological cells are intri-
cately layered with one another. To ensure the tumor
samples meet the standards for sequencing, a techni-
cian from POG who specialized in assessing and proc-
essing tumor tissues was present in the biopsy room.
The technician provided feedback to Dr Farred on the
quality of the samples based on their color and consis-
tency level. For example, a good liver tumor sample is
typically solid with a creamy consistency. Dr Farred
explained how you could touch the sample with a
gloved hand to feel whether it is harder, firmer, or
less elastic than the surrounding normal tissue. As
such, it was a collaborative feedback system between
Dr Farred and the technician to assess the quality of
the tumor sample using their bodily senses of sight and
touch.
Cancer, in a raw medical sense, refers to a patholog-
ical state of the cell and the flesh. At the biopsy stage,
cancer exhibits a physical state of color and consistency
that can be seen and touched. However, actors assess,
define, and negotiate the quality of the tumor based on
a feedback loop comprising two professional visions
(Goodwin, 1994) of both the radiologist and the tech-
nician. By using their touch and vision to assess the
quality of the tumor, both the radiologist and the tech-
nician “develop a feeling for” the tumor. This “feeling
for the tumour” requires a tacit form of knowledge to
measure what counts as creamy and firm tissues, and
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what counts as scanty and greasy tissues. Developing a
feeling for tumor echoes “a feeling for error” in which
scientists embody and materialize error to produce
“stable and accurate” data (Garnett, 2016), or in this
case, creamy and solid tissues. Hence, this visual feed-
back loop between the radiologist and the technician
put the tumor tissues, the object or the materiality of
the disease, on display or on stage, open for multiple
interpretations and discussion. This feedback commu-
nication between the radiologist and the technician
illustrates that the clinical gaze of assessing tumor is
not pure but mediated by different approaches to
ensure the tumor samples can yield sufficient data for
sequencing and Big Data analysis in the later steps of
the POG pipeline. At this biopsy stage, cancer exhibits
its pathological bodily properties that are socially
defined, negotiated and performed or enacted through
an amalgamation of different gazes between two med-
ical actors.
Pathology (molecular gaze): Spatial context of cells
and molecules under the microscope
The next step of the POG pipeline presents a point of
entry into the molecular gaze in which cancer is decom-
posed and understood in terms of protein expression
and translocation. After a roll of tissue is extracted
from the patient’s body, Dr Farred gave that roll of
sample to the technician to process. The technician
then applied a layer of optimal cutting temperature
(OCT) compound, a frozen chemical, in order to
freeze the tissue sample and preserve the best cellularity
quality content. Then, the OCT-tissue sample was
transferred to histopathology department at
Vancouver Cancer Centre for sectioning and quality
control. Histopathology is a medical specialty trained
in studying diseases using microscopic examination of
cells and tissues. The pathologist assesses the tumor
content and the tumor cellularity by looking under a
microscope.
In the microscopic view, the pathologist looks for
spatial contexts of the cells through the expression,
location, and nuclear translocation of proteins. The
pathologist then produces a report describing the type
of cancer, the size of the tumor, the invasiveness of the
tumor, the grade of the cancer reflecting how the
cancer cells look like in comparison with the normal
cells, the mitotic rate (or the rate of cells dividing), the
tumor margin, and the existence of cancer cells in
lymph nodes, blood vessels or other organs. While
the interventional radiologist defines cancer through
their clinical gaze of tumors in the form of ultrasound
images and creamy flesh, the pathologist exerts a
molecular gaze through the microscopic view of the
proteins embedded in the spatial contexts of cells and
tissues making up the cancer. However, the molecular
gaze of the pathologist is also hardly only molecular.
The pathologist focuses their gaze not only on the mol-
ecules but also on the cells along with their parts and
their environment. A leading pathologist at POG
explained the pathological assessment of cancer could
capture biological mechanisms of the cancer better
than the knowledge and information provided from
genomic sequencing. He argued that pathology could
examine both the expression of proteins and spatial
contexts of cells that make up the tumor, whereas he
described bioinformatic analysis of cancer as “a soup
of tumors, microenvironment and cells”. This compar-
ison highlights one of the epistemological differences
between pathology and bioinformatics, in which the
former enacts their knowledge about cancer through
studying tumors in relation to their microenvironment
while the latter combines all these elements in the
sequencing process and bioinformatic analysis to iden-
tify biomarkers and pathways that drive the cancer.
After the pathologist sections the biopsy samples,
they transfer them to the GSC building located a few
blocks away for DNA and RNA extraction of both the
tumor and blood samples. The extraction process cap-
tures the total nucleic acid (tNA) which contains both
DNA and RNA. Whole genome sequencing requires a
library for both DNA and RNA. The DNA library is
then used for genome sequencing, while the RNA
library is for transcriptome analysis. Whole genome
sequencing offers the complete orders of the entire
DNA sequences in one’s genome at a specific time.
Transcriptome sequencing provides insights into
altered expressions of genetic variants that underlie
the growth of the cancer cells. The name of the step,
“Library Core Construction,” reflects a liminal gaze
between molecular and informational in which the
DNA molecules are treated less as biological properties
but informational and textual objects that can be con-
structed into a library. In this step, DNA molecules are
sheered, chopped up, end repaired, size selected, added
with other tails for an exponential amplification. These
rigorous steps make us question the plasticity and
manipulability of our cells and molecules. Up until
this point, the patient body has only been rendered
molecular. She is about to become fully informational.
Bioinformatics (informational gaze) – Informational
production of cancer
To make sense of these DNA and RNA libraries con-
structed from the tumor and blood samples of the
patient requires the sequencing process. The DNA
and RNA libraries of the samples are then transferred
to the 6th floor at the GSC building for the sequencing
process. For each patient, POG typically sequences one
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blood DNA and three tumor DNA samples.
Sequencing these four samples requires reagents, a
chemical produced by the biotech company Illumina.
It costs roughly $10,000 CAD ($7650 USD) to
sequence a genome of one human being. These DNA
samples then go through a polymerase chain reaction
(PCR) process to rapidly amplify and extend into
500,000,000 clusters, each of which contains 1000 mol-
ecules (or strands of DNA). The PCR process was done
in a cBOT machine, which takes about 3.5 hours. After
PCR, the samples are transferred to an Illumina HiSeq
machine for sequencing, which contains two flow-cell
holders and a set of sophisticated cameras. These cam-
eras are set to take images that can signify locations
and markers of each A, C, G, or T nucleotides. The
final sequencing product is a large-scale file in a binary
base call (BCL) format, containing actual base sequen-
ces and indexes that are uploaded to a secured server.
The BCL file containing one human genome is about
600 GB in size. This dataset is then sent to bioinfor-
matics and genomic analyst teams for downstream
quality control and analysis. Subsequently, through
genome and transcriptome sequencing, DNA and
RNA molecules are fragmented, amplified, clustered,
cloned, and inscribed from biological specificities into
informational data and images.
Once the sequencing is uploaded, machine learning
algorithms automatically pick up the file, identify
cancer markers based on different probability values,
and generate an automatic report of relevant bio-
markers. Genome analysts will then assess the report
to construct a genomic pathway with detailed annota-
tion of “somatic single nucleotide and copy number
variants, indels, gene fusions, genome rearrangements,
and dysregulated gene expression pattern” (Laskin
et al., 2015: 7). The analyst generates three expression
metrics based on “a fold change in gene expression of
[the tumor] compared with a compendium of normal
tissues, a percentile ranking of gene expression within
similar tumor types, [drawing from The Cancer
Genome Atlas [TCGA] database], and a within-
sample expression rank of each gene” (p. 7). Hence,
the genomic pathway analysis is primarily concerned
with copy number changes, gene expression levels,
and percentile values of various markers that can pin-
point abnormalities. The pathway diagram and bioin-
formatic report are then sent to the clinician. At this
stage, the body/cancer is fully converted or inscribed
into numerical biomarkers and understood in terms of
percentile scores and levels of expression. The flesh,
cells, tissues, or molecules no longer hold an important
feature for bioinformatic analysis. Data points, scores,
numbers, and percentages of the genes now become the
main essence of the body. The molecular gaze has been
rendered into the informational gaze.
Thus far, we have “followed the samples’’ through
the POG pipeline to reflect the interactions between
clinical, molecular, and informational gaze. In these
gazes, the cancer takes on multiple forms, transitioning
from creamy tissues into tNA into sheered DNA and,
finally, into 600 GB data. At the bioinformatic stage,
cancer is no longer constituted of one single disease,
but now fractured into multiple mutations, biomarkers,
and pathways measured and understood in terms of
expression levels and percentile values. The process,
however, does not end here. A 600 GB of Big Data
does not automatically equate to clinical knowledge.
Rather, the translation of Big Data into clinical knowl-
edge requires constant negotiation, contestation, and
communication between different medical stakeholders
at POG. In some POG cases, the bioinformatic analysis
allows clinicians to change their course of diagnosis
and medical decision. However, in other cases, clini-
cians rely on their medical intuition and go against
the uncertainty posed by the genomic results. In the
next section, we explore a common challenge in Big
Data studies regarding the translatability of data into
practice. We delve into three vignettes that highlight
the interactions between the three systems of knowl-
edge, between pathology and bioinformatics and
between oncology and bioinformatics, in determining
what constitutes clinically actionable knowledge.
How genomic Big Data is translated into
actionable/meaningful knowledge?
In this section, we will recount three vignettes that
highlight the interactions between the various practices
at POG in their efforts to translate genomic Big Data
into actionable and meaningful knowledge. During the
fieldwork, the term “actionable” alone conveys many
ambiguities and contradictions among practitioners at
POG. To a clinician, actionable data referred to novel
variants being identified, and in turn, leading to an
alteration of clinical decisions. In the first vignette,
we recount a successful translation of Big Data into a
reclassification of cancer diagnosis. During an inter-
view with Harpreet, a PhD Candidate in
Bioinformatics, she shared how Big Data and machine
learning techniques employed in the bioinformatic
pipeline can unveil new insights, and at times, challenge
conventional methods in cancer diagnosis. In an article
recently published by the bioinformatic team at POG,
the team was able to employ supervised machine learn-
ing to revise diagnosis of an unknown primary cancer
from vulva to breast cancer (Grewal et al., 2017). The
initial pathology assessment for this patient with the
unknown primary cancer was poorly differential. The
pathologist suggested the patient might carry vulvar
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cancer. The bioinformatic team used machine learning
to compare the cancer against 27 different TCGA
cancer types, including breast and gynecologic cancers.
The result significantly correlated the cancer with
breast cancer and led to a “reclassification of the
tumor as a primary HER2þ mammary-like adenocar-
cinoma of the vulva” that most resembled genomic
profile of breast carcinomas (Grewal et al., 2017: 1).
The POG team confirmed the genomic analysis with
further immunohistology assessment. The oncologists
then prescribed the patient therapies targeting HER2þ
breast cancer.
This first vignette shows how Big Data and machine
learning can lead to fragmentation of a single disease
into multiple types based on biomarkers. This, in turn,
can reclassify disease types and treatment. Vulva cancer
was reclassified into the same group with breast cancer,
based on the shared similarity in HER2þ overexpres-
sion, and the patient’s treatment was altered with tar-
geted therapies of breast cancer. According to
Harpreet, machine learning algorithms in this case
were able to overcome uncertainties in pathology
assessment to pinpoint the exact tumor type of the
unknown primary cancer and revise treatment thera-
pies for the patient. As such, the genomic data in this
vignette was clinically actionable, as it successfully
identified notable variants that altered clinical diagno-
sis. This definition of “actionable” aligns with the char-
acteristics of actionability to most bioinformaticians.
However, in addition to the identification of notable
variants, actionability also “needs to be data-driven,”
according to a leading bioinformatician at POG. By
“data-driven,” the bioinformatician referred to a
myriad of statistical methods ranging from Bayesian
inference and probability to other computational algo-
rithms such as hidden Markov models, and evidence
collected from literature review and other clinical trials.
As such, what constitutes as “actionable” knowledge of
cancer and the body in the informational gaze follows
statistical logics of probability and inference that can
advance beyond conventional methods of diagnosis,
and in turn, reclassify disease and treatment.
In the second vignette, we show the perspective of
the pathologist toward “actionable data”. While the
bioinformatician is driven by data, information, and
statistics, the pathologist is driven by molecular struc-
tures of the body. Their visions and agendas for
“actionable knowledge” are different from that of bio-
informatician who is more driven by the validity and
utility of the data. To a leading pathologist in pancre-
atic cancer, “actionable” meant “actually doing some-
thing” that was “beneficial to the patient” either by
giving them a drug, re-defining the diagnosis, or over-
ruling the morphology. He went on to share with us an
interesting example that highlighted the limitations of
bioinformatics:
Bioinformaticians are people who look at the raw data
and distill the data based on the current knowledge
with an understanding of biology. Pathologists are
clinicians who are tasked with making a diagnosis.
So, my day to day [work] is to look through the
[micro]scope and make a diagnosis. I give you the
example, I don’t know what the POG number is, but
it is a case where a patient had a colorectal cancer and
they sequenced it and the bioinformatician presented
the data and told us that this is what it’s all about and
then we point it out them that the material that they
just sequenced is just stool. The point being here is that
as a bioinformatician you can find anything in the data
but if what you put in is not being adequately assessed
then what’s the point. So, there’s a huge difference
between pathology and bioinformatics. (Pathologist)
The example of “sequencing stool” shows the con-
straints faced by bioinformaticians who are dependent
on the other upstream roles, most particularly of the
pathologist and the radiologist, for the data they can
process and analyze. In other words, when the bioin-
formatician only comes to conceptualize the body
through data and information, they are constrained
by the very own data they can receive. The pathologist
further emphasized that the fundamental difference
between pathology and bioinformatics rested upon
their professional hierarchy:
We are MDs and they aren’t. We are clinicians. We
understand the impact of a diagnosis and what that
means. Bioinformaticians at the end of the day are
researchers and they are being given a set of data to
analyze something. The example I gave you earlier is
that they sequenced feces and they don’t know. The
whole point is, at the end of the day, everyone is depen-
dent on pathology on the right tissue to go forward.
(Pathologist)
This particular statement highlights a common attitude
of pathologists toward bioinformaticians who are con-
sidered to be on the lower end of the clinical hierarchy
as they are data researchers, rather than medical prac-
titioners. In his book “Life Out of Sequence,” historian
Hallam Stevens (2013) points out the fact that the def-
inition of “bioinformatics” is as ambiguous and widely
varied as the meaning of “actionability”. During his
fieldwork, he encounters various definitions regarding
bioinformatics. Some define bioinformatics as the
future, a convergence between biology and computers,
while others see it as limited sets of skills that do not
match up with the “real” biology. Some argue that
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bioinformatics generates new sorts of questions, while
others reckon that it only addresses conventional biol-
ogy questions with computational methods. This ambi-
guity about what counts as bioinformatics engenders
an identity problem for bioinformaticians who are
deemed to be an outsider to the medical community,
and yet still remaining as an integral part of a biomed-
ical pipeline. The first vignette shows the advance of
machine learning algorithms in reclassifying the exact
tumor type of a poorly differentiated vulvar cancer by
comparing the marker in a vast database. However, the
second vignette offers a nice contrast against the hype
around Big Data in which no matter how advanced
and powerful machine learning algorithms can be,
they are still heavily constrained and dependent on
other biological practices to produce meaningful
knowledge. As such, Big Data biology is still con-
strained and contingent upon the conventional biolog-
ical practices.
The last vignette of the article will highlight the lost
in translation or the lack of medical intuition between
actionable data and meaningful clinical knowledge. In
one of the gastric cancer cases, a patient at POG exhib-
its an overexpression of c-MET, which makes the
patient “genomically eligible” for c-Met inhibitor.
Bioinformatic analysis advised the clinician in charge
of her case to give the patient a drug of c-Met inhibitor.
However, the clinician did not agree with this genomic
result as they have “enough data” to believe otherwise:
There has been a randomized phase 3 trial stating that
c-MET inhibitor is actually detrimental to patients, so
we said no, we are not [going] do that. But the analyst
also points out, the trial is done on genomically unse-
lective patients, it’s not fair to do that. And I was like,
“we have a major randomized phase 3 trial that shows
inferiority. Ethically we can’t do that.” So, I think
sometimes we know some data that the analyst
doesn’t. Or at least the interpretation of the data
where we feel, although it’s a suggestion, ethically we
feel we have enough data to not give that treatment.
(Oncologist)
Actionable data to a bioinformatician does not neces-
sarily translate into clinically actionable knowledge for
a clinician. In this case above, the bioinformatic anal-
ysis identified c-Met as a biomarker responsible for the
growth of the patient’s cancer, and hence, recom-
mended a drug that would inhibit the expression of
c-Met. However, the clinician, drawing from their
own knowledge and literature review, believed that
c-Met inhibitor was detrimental for the patient with
gastric cancer. Therefore, they felt ethically responsible
not to prescribe the treatment. Clinicians tend to rely
on their professional intuition to sort out the
uncertainty of medical knowledge that may endanger
the wellbeing of their patient (Tessier, 2017).
Bioinformatician deems that the treatment decision
needs to be driven and supported by data. Clinicians,
however, have the clinical authority to render diagnos-
tic and treatments as well as carry an ethical responsi-
bility toward the wellbeing of the patient. In laboratory
research, it is more tolerable for a researcher to make
mistakes and learn from them. Many important scien-
tific discoveries happen by mistakes or accidents. In the
clinical setting, a mistake made by a doctor may cost a
human life. The clinical decisions impacting the well-
being of the patient, therefore, cannot solely be sup-
ported by Big Data and their statistical correlations.
When human cells, tissues and DNA are so abstracted
from our own identity, lab technicians and bioinforma-
ticians who work on DNA samples and analyze the
data mainly associate the patient as a number, rather
an individual. Thinking of the patient as a number
allows data scientists to remain scientifically objective
and base their treatment recommendations on Big
Data or statistical correlations, rather than intuition.
This rendering of a person and their pathology into
large-scale data is the underlying mechanism of POG,
or precision medicine on a broader scale. The third
vignette shows that the clinically actionable genomic
result did not necessarily translate into an ethically
sound therapeutic treatment. Medical intuition and
ethical responsibility of the clinician still holds higher
authority than data-driven knowledge in clinical deci-
sion-making.
Conclusion
Big Data has made deep and wide-reaching contribu-
tions to clinical medicine over the last 20 years since the
completion of the Human Genome Project. However,
the path from discovery to application has been a slow
and careful one. In the article, we describe and unpack
a transformation process of cancer tumors into Big
Data and the translatability of Big Data into clinical
knowledge. Our research engages with critical data
studies debate on the change versus continuity engen-
dered by Big Data in the medical setting. We do not
find the vision of Big Data having a strong revolution-
izing effect in cancer care. Instead, we find different
knowledge groups carefully and productively interact-
ing and contesting each other in the knowledge making
processes to produce and translate Big Data into clin-
ical decisions. POG’s production of Big Data from
cancer tumors requires an extensive network of collab-
oration among different medical practices from the
biopsy to the imaging processes in order to ensure the
sufficient quality of the samples for sequencing. As
such, clinical genomics is not purely data-driven but
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interdependent on different styles of (medical) thought,
gaze, and practice to be produced and made intelligible.
We also find, however, data-driven approaches to
understanding cancer engenders a structural shift in
the production of oncology knowledge by adding an
extra layer of data-driven evidence to understanding
cancer. Doctors are now increasingly collaborating
with a special kind of data scientist, bioinformaticians,
to understand genomic data and translate that into
their treatment decisions. This structural change, to a
certain extent, has led to an epistemological shift in
what counts as reliable or actionable knowledge in
understanding and treating cancer. Based on the first
vignette, Big Data and machine learning algorithms
can help the bioclinical collectives at POG to overcome
uncertainties in medical diagnosis. This generates an
ontological shift in the nature of cancer and treatment
itself. Cancer treatments are now understood less in
terms of pathology-based assessments than of
biomarker-driven approaches that regroup and reclas-
sify different cancers with shared biomarkers into the
same basket of treatment. However, the entrance of Big
Data does not equate to meaningful knowledge for
many practitioners at POG. In the second vignette,
the source of the Big Data was initially flawed with
the bioinformaticians sequencing and analyzing feces,
rather than cancer. In the third vignette, the knowledge
generated from the data was not aligned with the eth-
ical responsibilities or intuition of the doctor regardless
of how “data-driven” the therapeutic recommendation
was. Hence, to many doctors, the data-driven recom-
mendations, which underpins the mechanism of preci-
sion medicine, can contradict the medical ethics,
experience, and intuition of doctors to render
diagnosis.
This research also contributes to critical Big Data
and algorithm studies’ debates about power in knowl-
edge production. Producing oncology knowledge or
making clinical decisions creates interactions between
different stakeholders and communities of practice that
can cause conflict and challenges to hierarchy.
However, this research observes a different problem
that is equally important to understanding the nature
of interactions and collaboration between multidiscipli-
nary experts in clinical genomics. The ethnographic
data shows how the difference medical specialties oper-
ate from different gazes and how these multiple gazes
“hang together” to produce meaningful clinical knowl-
edge for cancer patients. Empirically, what lies at stake
of this collaborative network to produce and translate
Big Data into clinical decision is life itself, the life of the
patient. Our observations and interactions as research-
ers and collaborators with this line of clinical genomics
projects show less of a competition over hierarchical
position and more of a collaboration and convergence
of different stakeholders and fields to solve a common
problem. Of course, there is a gatekeeper at the end of
that collaboration and that is the oncologist. They are
the ones with the responsibility to choose a course of
treatment action. This decision can literally be a life or
death one. While there is a variation in the risk sensi-
tivity among cancer doctors, they all have the goal of
protecting the patient with treatment that has an
acceptable level of research studies and practical con-
sensus among their community.
This article also contributes a nuanced description
of the ontological paradox of personalized medicine to
science and technology studies and social studies of
medicine. The discourse surrounding personalized
medicine tends to focus on the benefits of personalizing
or individualizing health care. Barbara Prainsack
(2017) questions this very narrative in which she
argues personalized medicine thrives on the discourse
of empowering by individualizing patient care. Yet, in
reality that empowerment works in not the favor of the
patient, but of the new data economy through the
intense datafication of the patient body. As our article
has shown, although Big Data is embedded with com-
modity value, the fact that Big Data in oncology care is
still filtered through the clinical gaze of oncologists
means that the effects of data-commodification of pre-
cision medicine are tempered with medical intuition
and ethics in medical settings. This paradox of person-
alized medicine is best captured with a response from
one of the pathologists who argued that whichever gaze
one employs to understand cancer, the ultimate goal
should not be for “knowledge sake,” or for the domi-
nance of one specialty over another but for “[finding]
the cure” to “kill the cancer” for the benefit of the most
important stakeholder, the patient:
We’re doing this because we want to kill the cancer
(. . .) In some ways I don’t care how we get there,
whether we do it by protein expression or gene expres-
sion profiling, as long as we find the cure. That’s what
I want. I think the two of us, bioinformaticians and
clinicians and pathologist should have that goal in
mind. Some people might not have that goal in mind,
like they couldn’t care less if they cure it or not. They
just want to know more about it right. I don’t know
who those people are, but I’m sure those exist right,
like they just want to know it for knowledge sake. But I
think if you work with real life patient and you’re
making decisions for them, then you should have that
goal of we want to make their lives better. I think when
you lose that focus, then you’ll start getting into things
that might harm, then you would start to say, “oh well
this is likely elevated so let’s just try this inhibitor or
whatever,” right, you start to lose focus on whether
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that is really in the best interest of the patient.
(Pediatric pathologist)
This pathologist expressed a common, if not the dom-
inant, sentiment among all actors and specialties in
POG. She acknowledged there may be some who
have scientific knowledge as their main goal, but also
said she did not know them personally. What we think
she meant was that putting the life of the patient first
and science and career second contributes to a culture
of collaboration rather than conflict. This is also a
reminder for medical practitioners about what is at
stake for our personhood and subjectivity as well as
medical intuition and ethics when our body and pathol-
ogy is replaced or abstracted into large-scale data.
Precision medicine reduces the patient’s personhood
to Big Data, abstract numbers, and statistical corre-
lations in order to produce data-driven recommenda-
tions for therapeutic treatment. Seeing the body as an
information system is an extension of the clinical gaze
that sees life as a natural resource in the forms of Big
Data for extraction and appropriation. The “data
fever” of the genome scientist discussed earlier exem-
plifies a data-driven social order (Couldry and Mejias,
2019) in coming to know the self and the world.
However, to a clinician, the wellbeing and personhood
of the patient still holds an utmost importance in their
professional and ethical responsibility. Consequently,
this produces a paradox of personalized medicine in
which data abstracts personhood to produce objec-
tive, data-driven knowledge, and yet this lack of per-
sonhood can engender a gap in translation of
actionable data into clinically meaningful knowledge.
This is not a critique against the critical work that
our participants do to save lives. By no means do
we contend that the doctors and scientists are exploit-
ing the patients. Rather, we have showed how replac-
ing our personhood by large-scale data and numbers
can both enable new understanding about cancer
treatments and constrain traditional forms of medical
knowledge and intuition about the body along with
its pathology.
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